BACKGROUND AND AIMS: Recent studies have shown no detectable antibodies and no response to a challenge dose of vaccine 10-20 y after receiving low doses (2.5-5 µg) of recombinant hepatitis B vaccine during first months of life. Little information is available on long-term persistence of immunity after vaccinating pre-adolescents with low doses of hepatitis B vaccine. RESULTS: The results of 560 subjects were included in this analysis. All subjects had a seroprotective antibody titer (≥10 IU/L) one month post-primary vaccination; 5, 10 and 15 y post-vaccination 95%, 95% and 87% had detectable antibodies, and 82%, 86%, and 68% had a seroprotective antibody titer; GMTs were 73 IU/L, 89 IU/L, and 28 IU/L, respectively. More than 99.4% of subjects had an anamnestic response to a challenge dose of vaccine given 5, 10, or 15 y post-vaccination. Five and ten years post-booster dose 97% and 95% of subjects still have a seroprotective anti-HBs titer with GMTs 16-18-fold higher when compared with those observed 5-10 y post-primary vaccination. MATERIALS AND METHODS: This randomized trial was initiated in 1996 with the main objective to assess the persistence of antibodies and immune memory 5, 10 and 15 y after vaccinating 8-10 y-old children with three doses of Recombivax 2.5 µg, as well as the short and long-term effect of a booster dose given at different intervals. CONCLUSIONS: Virtually all children vaccinated at the age of 8-10 y with low doses of hepatitis B vaccine still have an excellent immune memory up to age of 25 y. The results of this study do not support the use of booster doses.
RCT Entities:
BACKGROUND AND AIMS: Recent studies have shown no detectable antibodies and no response to a challenge dose of vaccine 10-20 y after receiving low doses (2.5-5 µg) of recombinant hepatitis B vaccine during first months of life. Little information is available on long-term persistence of immunity after vaccinating pre-adolescents with low doses of hepatitis B vaccine. RESULTS: The results of 560 subjects were included in this analysis. All subjects had a seroprotective antibody titer (≥10 IU/L) one month post-primary vaccination; 5, 10 and 15 y post-vaccination 95%, 95% and 87% had detectable antibodies, and 82%, 86%, and 68% had a seroprotective antibody titer; GMTs were 73 IU/L, 89 IU/L, and 28 IU/L, respectively. More than 99.4% of subjects had an anamnestic response to a challenge dose of vaccine given 5, 10, or 15 y post-vaccination. Five and ten years post-booster dose 97% and 95% of subjects still have a seroprotective anti-HBs titer with GMTs 16-18-fold higher when compared with those observed 5-10 y post-primary vaccination. MATERIALS AND METHODS: This randomized trial was initiated in 1996 with the main objective to assess the persistence of antibodies and immune memory 5, 10 and 15 y after vaccinating 8-10 y-old children with three doses of Recombivax 2.5 µg, as well as the short and long-term effect of a booster dose given at different intervals. CONCLUSIONS: Virtually all children vaccinated at the age of 8-10 y with low doses of hepatitis B vaccine still have an excellent immune memory up to age of 25 y. The results of this study do not support the use of booster doses.
Entities:
Keywords:
hepatitis B; immunity; long term; persistence; vaccination
Authors: Vladimir Gilca; Gaston De Serres; Nicole Boulianne; Donald Murphy; Philippe De Wals; Manale Ouakki; Gisele Trudeau; Richard Massé; Marc Dionne Journal: Vaccine Date: 2012-12-01 Impact factor: 3.641
Authors: Sandra S Chaves; Gayle Fischer; Justina Groeger; Priti R Patel; Nicola D Thompson; Eyasu H Teshale; Kuartei Stevenson; Victor M Yano; Gregory L Armstrong; Taraz Samandari; Saleem Kamili; Jan Drobeniuc; Dale J Hu Journal: Vaccine Date: 2012-01-11 Impact factor: 3.641
Authors: Roman Chlibek; Frank von Sonnenburg; Pierre Van Damme; Jan Smetana; Petr Tichy; Bhavyashree Gunapalaiah; Maarten Leyssen; Jeanne-Marie Jacquet Journal: J Travel Med Date: 2011-02-07 Impact factor: 8.490
Authors: Pavel Teoharov; Ani Kevorkyan; Nedyalka Petrova; Ivan Baltadzhiev; Pierre Van Damme Journal: Pediatr Infect Dis J Date: 2013-01 Impact factor: 2.129
Authors: Laura L Hammitt; Lisa Bulkow; Thomas W Hennessy; Carolyn Zanis; Mary Snowball; James L Williams; Beth P Bell; Brian J McMahon Journal: J Infect Dis Date: 2008-12-15 Impact factor: 5.226
Authors: Stephanie R Bialek; William A Bower; Ryan Novak; Louisa Helgenberger; Steven B Auerbach; Ian T Williams; Beth P Bell Journal: Pediatr Infect Dis J Date: 2008-10 Impact factor: 2.129
Authors: Pierre Van Damme; Geert Leroux-Roels; P Suryakiran; Nicolas Folschweiller; Olivier Van Der Meeren Journal: Hum Vaccin Immunother Date: 2017-03-10 Impact factor: 3.452